Galecto Inc (GLTO) Stock Price, Quote & News

Company Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 52 10

Website: galecto.com

Address:

Ole Maaloes Vej 3, Copenhagen N, Copenhagen, Denmark

JohnTrack Jan. 12 at 3:10 PM

$GLTO watching range resolve!

0 · Reply

JohnTrack Jan. 12 at 1:15 PM

$GLTO short notice https://www.rapidticker.com/news/glto-sec-filing-e1c33a

0 · Reply

Stockwatcher9999 Jan. 9 at 9:07 PM

$GLTO it will be nice when they sort out shares outstanding and market cap. im tempted but have no idea what valuation im buying at…

0 · Reply

RowanG Jan. 9 at 8:51 PM

$MLTX nice. This could be like $GLTO ...moved big AH and PM.

0 · Reply

GHECKO Jan. 9 at 4:33 PM

$GLTO bro …

0 · Reply

JohnTrack Jan. 6 at 5:39 PM

$GLTO light watch, nothing crazy...

0 · Reply

JohnTrack Jan. 6 at 1:43 PM

$GLTO update just released... https://www.rapidticker.com/news/glto-sec-filing-562761

0 · Reply

Investor1337 Jan. 1 at 7:51 PM

$GLTO Is GB1211 still being investigated with pembru and ATZ?

1 · Reply

SuperGreenToday Jan. 1 at 12:36 AM

$GLTO

0 · Reply

JohnTrack Dec. 31 at 10:07 PM

$GLTO latest line about this stock https://www.rapidticker.com/news/glto-sec-filing-7e59d6

0 · Reply

Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 1:08 PM EST - 2 months ago

GLTO, MOVE: two penny stocks quadrupled today – but should you buy?

MOVE

Nov 10, 2025, 11:47 AM EST - 2 months ago

Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029

Nov 10, 2025, 7:00 AM EST - 2 months ago

Galecto Announces Acquisition of Damora Therapeutics

Nov 6, 2025, 4:30 PM EST - 2 months ago

Galecto Reports Third Quarter 2025 Operating and Financial Results

Oct 7, 2025, 1:05 PM EDT - 3 months ago

What's Going On With Nano-Cap Galecto Stock On Tuesday?

Oct 7, 2025, 10:27 AM EDT - 3 months ago

Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble

Aug 5, 2025, 4:15 PM EDT - 5 months ago

Galecto Reports Second Quarter 2025 Operating and Financial Results

May 8, 2025, 4:30 PM EDT - 8 months ago

Galecto Reports First Quarter 2025 Operating and Financial Results

Mar 19, 2025, 4:45 PM EDT - 10 months ago

Galecto Reports Full-Year 2024 Financial Results

Feb 6, 2025, 8:00 AM EST - 1 year ago

Galecto to Participate in Upcoming Investor Conferences

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Galecto Reports Third Quarter 2024 Financial Results

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Oct 7, 2024, 8:45 AM EDT - 1 year ago

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Aug 28, 2024, 9:00 AM EDT - 1 year ago

Galecto Announces Reverse Stock Split

May 1, 2024, 4:01 PM EDT - 1 year ago

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Dec 21, 2023, 4:05 PM EST - 2 years ago

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Sep 26, 2023, 4:01 PM EDT - 2 years ago

Galecto Announces Plans to Explore Strategic Alternatives

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GALT

Aug 31, 2023, 11:00 AM EDT - 2 years ago

Galecto to Present at Investor Conferences in September

Aug 15, 2023, 8:39 AM EDT - 2 years ago

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Aug 15, 2023, 7:55 AM EDT - 2 years ago

Galecto to discontinue development of lung disease treatment

Aug 15, 2023, 7:30 AM EDT - 2 years ago

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Jul 31, 2023, 4:05 PM EDT - 2 years ago

Galecto Reports Second Quarter Operating and Financial Results

Jun 20, 2023, 8:58 AM EDT - 2 years ago

Galecto Set to Join Russell Microcap® Index

May 30, 2023, 8:00 AM EDT - 2 years ago

Galecto to Present at the Upcoming Jefferies Healthcare Conference

May 23, 2023, 8:30 AM EDT - 2 years ago

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

May 17, 2023, 4:01 PM EDT - 2 years ago

Galecto to Present Poster at Upcoming ATS 2023 International Conference

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Galecto Reports First Quarter Operating and Financial Results

Apr 18, 2023, 7:01 PM EDT - 2 years ago

Galecto: Promising Pipeline And Excellent Risk-Reward

Apr 13, 2023, 8:30 AM EDT - 2 years ago

Galecto to Present Two Posters at AACR Annual Meeting 2023

Mar 9, 2023, 7:00 AM EST - 3 years ago

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Mar 2, 2023, 4:05 PM EST - 3 years ago

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Feb 1, 2023, 8:00 AM EST - 3 years ago

Galecto to Participate in SVB Securities Global Biopharma Conference

Dec 7, 2022, 4:05 PM EST - 3 years ago

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Nov 8, 2022, 9:15 AM EST - 3 years ago

Galecto Reports Third Quarter Operating and Financial Results

Nov 8, 2022, 6:00 AM EST - 3 years ago

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Nov 3, 2022, 8:00 AM EDT - 3 years ago

Galecto to Participate in Jefferies London Healthcare Conference

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Oct 19, 2022, 8:00 AM EDT - 3 years ago

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Oct 17, 2022, 6:00 AM EDT - 3 years ago

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Sep 29, 2022, 10:11 AM EDT - 3 years ago

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

Sep 29, 2022, 6:00 AM EDT - 3 years ago

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Sep 6, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Aug 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

May 31, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at Jefferies Healthcare Conference

May 26, 2022, 8:30 AM EDT - 3 years ago

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Apr 26, 2022, 8:30 AM EDT - 4 years ago

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Mar 29, 2022, 8:30 AM EDT - 4 years ago

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

JohnTrack Jan. 12 at 3:10 PM

$GLTO watching range resolve!

0 · Reply

JohnTrack Jan. 12 at 1:15 PM

$GLTO short notice https://www.rapidticker.com/news/glto-sec-filing-e1c33a

0 · Reply

Stockwatcher9999 Jan. 9 at 9:07 PM

$GLTO it will be nice when they sort out shares outstanding and market cap. im tempted but have no idea what valuation im buying at…

0 · Reply

RowanG Jan. 9 at 8:51 PM

$MLTX nice. This could be like $GLTO ...moved big AH and PM.

0 · Reply

GHECKO Jan. 9 at 4:33 PM

$GLTO bro …

0 · Reply

JohnTrack Jan. 6 at 5:39 PM

$GLTO light watch, nothing crazy...

0 · Reply

JohnTrack Jan. 6 at 1:43 PM

$GLTO update just released... https://www.rapidticker.com/news/glto-sec-filing-562761

0 · Reply

Investor1337 Jan. 1 at 7:51 PM

$GLTO Is GB1211 still being investigated with pembru and ATZ?

1 · Reply

SuperGreenToday Jan. 1 at 12:36 AM

$GLTO

0 · Reply

JohnTrack Dec. 31 at 10:07 PM

$GLTO latest line about this stock https://www.rapidticker.com/news/glto-sec-filing-7e59d6

0 · Reply

michaelburryburner Dec. 30 at 8:57 PM

$GLTO interesting

0 · Reply

P4jt Dec. 30 at 7:44 PM

$GLTO Huge money making short…..OVER AND OVER AGAIN…CHEERSP4

0 · Reply

UgoGreg Dec. 30 at 6:21 PM

$GLTO https://youtu.be/IMNuQJWP_ts

0 · Reply

opmankc Dec. 29 at 12:36 PM

$GLTO the newly merged share holders will come into share market soon. prepare to buy or hold and make up your mind The Selling Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus forms a part.

0 · Reply

DragonSlayer12 Dec. 27 at 9:18 PM

$GLTO $100-200 come Monday crazy squeeze similar to $ASPC here

1 · Reply

JordanBelfortz Dec. 26 at 8:38 PM

$GLTO really not liking this wall at $35, but we’ll get there. Not a ton of support, but looks like we have some at $26. As we all know, pharma is volatile, so manage the risk! With that said…I like a bounce to ~$42.75, a retest at the $35 level, then the next zone is $52.85, we’ll see! Have a great weekend all!

0 · Reply

opmankc Dec. 26 at 7:49 PM

$GLTO Get ready to buy the offering https://www.sec.gov/Archives/edgar/data/1800315/000119312525321093/d60916ds3.htm

1 · Reply